STOCK TITAN

SS Innovations International (SSII) SEC Filings, May-Jun 2026

SSII NASDAQ

SS Innovations International Inc. filings document a Nasdaq-listed surgical robotics issuer and its formal disclosures around the SSi Mantra platform. Recent Current Reports on Form 8-K record product and regulatory updates, telesurgery announcements, conference-related disclosures, financial-results releases and Regulation FD communications.

The filing record also covers capital structure events, including an unregistered private placement of common stock, and identifies the company’s common stock as registered on Nasdaq under SSII. Annual-report and current-report disclosures provide formal context for operating results, product development, clinical and regulatory timelines, forward-looking statements, and the company’s subsidiary-based reporting perimeter.

Rhea-AI Summary

SS Innovations International, Inc. insider Barry F. Cohen, who serves as COO - Americas and a director, reported a bona fide gift of 25,000 shares of Common Stock. The transaction carried a stated price of $0.00 per share. After the gift, he directly holds 7,755,088 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.48%
Tags
insider
-
Rhea-AI Summary

SS Innovations International, Inc. reported a senior leadership change. On May 18, 2026, Milan Rao informed the company he will step down as Global Chief Operating Officer and Chief Financial Officer, effective May 25, 2026.

The company stated that it has begun a search process to identify and recruit a permanent successor for the Chief Financial Officer role. No additional details about interim arrangements or reasons for the departure are provided in this report.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.80%
Tags
current report
-
Rhea-AI Summary

SS Innovations International, Inc. files a shelf prospectus to register up to $150,000,000 of securities and to permit resale of up to 5,016,500 shares of common stock by selling shareholders.

The prospectus registers multiple securities types (common stock, preferred, warrants, rights, units, debt) and specifically covers 5,016,500 Shares comprised of shares sold in a March 6, 2026 private placement, and shares issuable upon exercise of RCP Warrants (41,667 shares, $3.45 exercise) and HCW Warrants (500,000 shares, $8.89 exercise). The company will receive proceeds only if those warrants are exercised.

The filing describes the SSi Mantra surgical robotic system, regulatory filings including a 510(k) submission to the FDA, an installed base of 194 systems as of March 31, 2026, and cumulative use in 9,744 procedures. The prospectus discloses concentrated control by Dr. Sudhir Srivastava (approx. 55.84% beneficial ownership) and material risk factors including continued losses, regulatory and manufacturing risks, and the need for additional financing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
prospectus
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
other
-
Rhea-AI Summary

SS Innovations International, Inc. insider reporting shows an "other" type transaction involving indirect holdings associated with Chairman and CEO Sudhir Srivastava. An entity he controls, Sushruta Pvt. Ltd., transferred 21,506 shares of common stock at $5.0000 per share.

The transfer was made pursuant to a settlement agreement dated May 4, 2026. After this restructuring, Sushruta Pvt. Ltd. is reported as holding 109,564,261 shares of SS Innovations common stock indirectly for Srivastava, indicating the transaction is very small relative to his overall position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
-
Rhea-AI Summary

SS Innovations International, Inc. reported record unaudited first quarter 2026 revenue of $11.1 million, up about 117% from $5.1 million a year earlier, driven mainly by higher SSi Mantra system and instrument sales. System sales rose to $9.6 million and instruments to $1.2 million, while total revenue increased 116.8%.

Gross profit expanded to $5.3 million from $1.1 million. The company still posted a net loss of $3.6 million, but this improved from a $5.7 million loss in the prior-year quarter as operating loss narrowed. Installations of the SSi Mantra system grew to 26 in the quarter, with a cumulative installed base of 194 systems and 1,859 surgeries performed.

Liquidity strengthened significantly. Cash flows from financing activities included $18.6 million in gross proceeds from a March 2026 private placement, contributing to cash and cash equivalents of $24.0 million at March 31, 2026. Management highlighted ongoing regulatory efforts, including U.S. FDA review of a 510(k) submission and progress toward European Union CE marking for the SSi Mantra.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
current report
Rhea-AI Summary

SS Innovations International, Inc. reported strong top-line growth but continued losses for the three months ended March 31, 2026. Revenue rose to $11,101,366 from $5,120,610 a year earlier, driven mainly by higher system sales.

The company posted a net loss of $3,582,571, improving from a $5,681,353 loss, with results heavily affected by non-cash stock compensation of $3,144,315 and depreciation of $323,747. Cash, cash equivalents and restricted cash increased to $24,005,680, helped by a private placement that generated net proceeds of $18,446,498.

Despite a working capital surplus of $40,216,514, management disclosed that recurring losses, dependence on related-party funding, and insufficient projected cash flows raise substantial doubt about the company’s ability to continue as a going concern over the next 12 months, absent additional financing and successful execution of growth plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
quarterly report
-
Rhea-AI Summary

SS Innovations International, Inc. reported a milestone demonstration of its robotic telesurgery technology. The company announced a successful long-distance cross-border procedure using the SSi Mantra surgical robotic system and the SSi MantrAsana tele-surgeon console, connecting a surgeon in Perth, Australia with a patient in Indore, India over more than 4,500 miles.

On May 2, 2026, Dr. Mohit Bhandari remotely performed a robotic gastrojejunostomy during the Royal Australian College of Surgeons Annual Scientific Congress using the portable SSi MantrAsana console. The company notes that more than 170 telesurgeries, including complex cardiac procedures, have now been completed with SSi Mantra, which has been clinically validated in India in over 100 types of surgical procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
current report
-
Rhea-AI Summary

SS Innovations International, Inc. reported that more than 10,500 cumulative surgeries have been successfully performed using its SSi Mantra surgical robotic system as of April 30, 2026. These include over 500 cardiac procedures, 170 telesurgeries, and 125 pediatric surgeries across multiple specialties.

The company has installed more than 200 SSi Mantra systems in eleven countries and trained approximately 2,100 physicians, with the platform used in over 170 different procedure types. Management highlights technology features, user-friendliness, and cost advantages as drivers of adoption since commercial launch in August 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.70%
Tags
current report
Rhea-AI Summary

SS Innovations International, Inc. reports amended beneficial ownership by Sudhir Srivastava and Sushruta PVT LTD. Sudhir Srivastava beneficially owns 114,490,054 shares, representing 55.8% of the outstanding common stock. Sushruta PVT LTD holds 109,585,767 shares, representing 54.7%. The percentages are calculated using 200,231,535 shares outstanding as of March 9, 2026, per the company’s amended Form 10-K/A. The filing states Dr. Srivastava has a 100% interest in Sushruta PVT LTD and that his reported position includes options to purchase 4,872,287 shares and a direct holding of 32,000 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.70%
Tags
ownership

FAQ

How many SS Innovations International (SSII) SEC filings are available on StockTitan?

StockTitan tracks 93 SEC filings for SS Innovations International (SSII), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for SS Innovations International (SSII)?

The most recent SEC filing for SS Innovations International (SSII) was filed on November 19, 2026.